Tag: reimbursement-risk
-
Boston Scientific Stock Analysis (BSX): Growth at a Premium
Boston Scientific (BSX) earns a Buy rating on double-digit revenue growth, expanding EBITDA, and improving free cash flow. The key question is whether management can sustain execution while navigating reimbursement pressure and acquisition-led capital deployment.